Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

700
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
700
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.2K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

418
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
418
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.2K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.2K
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

931
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
931

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults with Depression and Mild Cognitive Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Can Psychedelics Help Us Reimagine Prevention of Posttraumatic Stress Disorder?

Biological psychiatry·2026
Same author

Role of the Locus Coeruleus in Response to Threat in Anxiety Disorders and Posttraumatic Stress Disorder: An Ultra-High-Field 7T Functional Magnetic Resonance Imaging Study.

Biological psychiatry global open science·2025
Same author

Factors Influencing Perceived Mental Health Service Needs, Self-reported Utilization, and Barriers to Care Among Health System Faculty and Staff.

Journal of occupational and environmental medicine·2025
Same author

Association of Psychological Resilience With Decelerated Brain Aging in Cognitively Healthy World Trade Center Responders.

Biological psychiatry global open science·2025
Same author

Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.

The Journal of clinical psychiatry·2025

Video Experimental Relacionado

Updated: Dec 25, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K

Un nuevo antidepresivo de acción rápida

John H Krystal1, Dennis S Charney1, Ronald S Duman1

  • 1Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA.

Cell
|April 4, 2020
PubMed
Resumen
Este resumen es generado por máquina.

El descubrimiento de los rápidos efectos antidepresivos de la r/s-cetamina ofrece nuevas perspectivas biológicas. Esto llevó a la aprobación de la FDA de Esketamine (Spravato), un nuevo tratamiento para la depresión.

Más Videos Relacionados

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

454

Videos de Experimentos Relacionados

Last Updated: Dec 25, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

454

Área de la Ciencia:

  • La neurociencia
  • Farmacología
  • La psiquiatría

Sus antecedentes:

  • La depresión resistente al tratamiento (TRD, por sus siglas en inglés) sigue siendo un reto clínico importante.
  • Las terapias antidepresivas existentes tienen limitaciones en cuanto a eficacia y velocidad de acción.
  • Los mecanismos biológicos que subyacen a la depresión no se comprenden completamente.

Objetivo del estudio:

  • Para resaltar el descubrimiento de los rápidos efectos antidepresivos de la r/s-ketamina.
  • Para discutir las implicaciones para entender la biología antidepresiva.
  • Para informar de la aprobación de la FDA de Esketamina (Spravato) para la depresión.

Principales métodos:

  • Revisión de los estudios preclínicos y clínicos sobre los efectos antidepresivos de la ketamina.
  • Análisis de las propiedades farmacológicas de la ketamina y sus isómeros.
  • Examen de la vía reguladora que conduce a la aprobación de la esketamina.

Principales resultados:

  • r/ s-ketamina muestra efectos antidepresivos rápidos y robustos en pacientes con TRD.
  • Estos hallazgos han proporcionado nuevos conocimientos sobre la neurobiología de la depresión y la acción antidepresiva.
  • La esketamina (Spravato), el isómero S de la ketamina, recibió la aprobación de la FDA.

Conclusiones:

  • La ketamina representa un nuevo enfoque terapéutico para la depresión.
  • La escetamina (Spravato) ofrece una nueva opción de tratamiento para las personas con depresión resistente a los antidepresivos.
  • Las investigaciones adicionales sobre los mecanismos de la ketamina pueden dar lugar a estrategias terapéuticas adicionales.